Reimagining Medicine

Company overview Financial review Conclusions Appendix References Next steps for KisqaliⓇ Continued momentum in mBC, with increasing market share and NATALEE updated analysis for iDFS and OS expected H2 2023 prescriber adoption INNOVATION Expected filing in EU and US Q3/Q4 2023 Pursuing broad label reflecting the ITT population studied in NATALEE Collectively, NATALEE results¹ have the potential to more than double the number of patients² who could benefit from treatment with a CDK4/6 inhibitor in the eBC setting ITT Intent to treat. 1. Interim analysis. 2. Pending regulatory review and approval. 10 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation